Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTLT11V1)

• DOT Name: Mucin-4 (MUC4)
• Synonyms: MUC-4; Ascites sialoglycoprotein; ASGP; Pancreatic adenocarcinoma mucin; Testis mucin; Tracheobronchial mucin
• Gene Name: MUC4
• Related Disease:
  Clear cell renal carcinoma
  Matthew-Wood syndrome
  Mucositis
  Advanced cancer
  Bone osteosarcoma
  Carcinoma
  Cervical cancer
  Cervical carcinoma
  Cholangiocarcinoma
  Colon cancer
  Colon carcinoma
  Colorectal carcinoma
  Corneal neovascularization
  Cystic fibrosis
  Esophageal cancer
  Gastric cancer
  Hepatocellular carcinoma
  HER2/NEU overexpressing breast cancer
  Inflammatory bowel disease
  Lung adenocarcinoma
  Lung cancer
  Lung carcinoma
  Nasal polyp
  Nematode infection
  Osteosarcoma
  Otitis media
  Ovarian cancer
  Papillary renal cell carcinoma
  Prostate carcinoma
  Renal cell carcinoma
  Sickle-cell anaemia
  Squamous cell carcinoma
  Stomach cancer
  Breast cancer
  Breast carcinoma
  Gastric neoplasm
  Pancreatic adenocarcinoma
  Metastatic malignant neoplasm
  Adenocarcinoma
  Fetal growth restriction
  Pancreatic ductal carcinoma
  Prostate cancer
  Prostate neoplasm
• UniProt ID: MUC4_HUMAN
• Pfam ID: PF06119 ; PF00094
• Sequence:
  MKGARWRRVPWVSLSCLCLCLLPHVVPGTTEDTLITGSKTAAPVTSTGSTTATLEGQSTA
  ASSRTSNQDISASSQNHQTKSTETTSKAQTDTLTQMMTSTLFSSPSVHNVMETAPPDEMT
  TSFPSSVTNTLMMTSKTITMTTSTDSTLGNTEETSTAGTESSTPVTSAVSITAGQEGQSR
  TTSWRTSIQDTSASSQNHWTRSTQTTRESQTSTLTHRTTSTPSFSPSVHNVTGTVSQKTS
  PSGETATSSLCSVTNTSMMTSEKITVTTSTGSTLGNPGETSSVPVTGSLMPVTSAALVTF
  DPEGQSPATFSRTSTQDTTAFSKNHQTQSVETTRVSQINTLNTLTPVTTSTVLSSPSGFN
  PSGTVSQETFPSGETTTSSPSSVSNTFLVTSKVFRMPTSRDSTLGNTEETSLSVSGTISA
  ITSKVSTIWWSDTLSTALSPSSLPPKISTAFHTQQSEGAETTGRPHERSSFSPGVSQEIF
  TLHETTTWPSSFSSKGHTTWSQTELPSTSTGAATRLVTGNPSTGTAGTIPRVPSKVSAIG
  EPGEPTTYSSHSTTLPKTTGAGAQTQWTQETGTTGEALLSSPSYSVTQMIKTATSPSSSP
  MLDRHTSQQITTAPSTNHSTIHSTSTSPQESPAVSQRGHTQAPQTTQESQTTRSVSPMTD
  TKTVTTPGSSFTASGHSPSEIVPQDAPTISAATTFAPAPTGDGHTTQAPTTALQAAPSSH
  DATLGPSGGTSLSKTGALTLANSVVSTPGGPEGQWTSASASTSPDTAAAMTHTHQAESTE
  ASGQTQTSEPASSGSRTTSAGTATPSSSGASGTTPSGSEGISTSGETTRFSSNPSRDSHT
  TQSTTELLSASASHGAIPVSTGMASSIVPGTFHPTLSEASTAGRPTGQSSPTSPSASPQE
  TAAISRMAQTQRTRTSRGSDTISLASQATDTFSTVPPTPPSITSTGLTSPQTETHTLSPS
  GSGKTFTTALISNATPLPVTYASSASTGHTTPLHVTDASSVSTGHATPLPVTSPSSVSTG
  HTTPLPVTDTSSESTGHVTPLPVTSFSSASTGDSTPLPVTDTSSASTGHVTPLPVTSLSS
  ASTGDTTPLPVTDTSSASTGHATSLPVTDTSSVSTGHTTPLPVTDTSSASTGHATSLPVT
  DTSSVSTGHTTPLHVTDASSASTGQATPLPVTSLSSVSTGDTTPLPVTSPSSASTGHATP
  LLVTDTSSASTGHATPLPVTDASSVSTDHATSLPVTIPSAASTGHTTPLPVTDTSSASTG
  QATSLLVTDTSSVSTGDTTPLPVTSTSSASTGHVTPLHVTSPSSASTGHATPLPVTSLSS
  ASTGDTMPLPVTSPSSASTGDTTPLPVTDASSVSTGHTTPLHVTDASSASTGQATPLPVT
  SLSSVSTGDTTPLPVTSPSSASTGHATPLLVTDTSSASTGHATPLPVTDASSVSTDHATS
  LPVTIPSAASTGHTTPLPVTDTSSASTGQATSLLVTDTSSVSTGDTTPLPVTSTSSASTG
  HVTPLHVTSPSSASTGHATPLPVTSLSSASTGDTMPLPVTSPSSASTGDTTPLPVTDASS
  VSTGHTTPLPVTSPSSASTGHTTPLPVTDTSSASKGDTTPLPVTSPSSASTGHTTPLPVT
  DTSSASTGDTTPLPVTNASSLSTGHATPLHVTSPSSASTGHATPLPVTSTSSASTGHATP
  LPVTGLSSATTDDTTRLPVTDVSSASTGQATPLPVTSLSSVSTGDTTPLPVTSPSSASTG
  HASPLLVTDASSASTGQATPLPVTDTSSVSTAHATPLPVTGLSSASTDDTTRLPVTDVSS
  ASTGQAIPLPVTSPSSASTGDTTPLPVTDASSASTGDTTSLPVTIPSSASSGHTTSLPVT
  DASSVSTGHATSLLVTDASSVSTGDTTPLPVTDTNSASTGDTTPLHVTDASSVSTGHATS
  LPVTSLSSASTGDTTPLPVTSPSSASSGHTTPLPVTDASSVPTGHATSLPVTDASSVSTG
  HATPLPVTDASSVSTGHATPLPVTDTSSVSTGQATPLPVTSLSSASTGDTTPLPVTDTSS
  ASTGQDTPLPVTSLSSVSTGDTTPLPVTNPSSASTGHATPLLVTDASSISTGHATSLLVT
  DASSVSTGHATALHDTDASSLSTGDTTPLPVTSPSSTSTGDTTPLPVTETSSVSTGHATS
  LPVTDTSSASTGHATSLPVTDTSSASTGHATPLPVTDTSSASTGQATPLPVTSPSSASTG
  HAIPLLVTDTSSASTGQATPLPVTSLSSASTGDTTPLPVTDASSVSTGHATSLPVTSLSS
  VSTGDTTPLPVTSPSSASTGHATPLHVTDASSASTGHATPLPVTSLSSASTGDTTPLPVT
  SPSSASTGHATPLHVTDASSVSTGDTTPLPVTSSSSASSGHTTPLPVTDASSASTGDTTP
  LPVTDTSSASTGHATHLPVTGLSSASTGDTTRLPVTNVSSASTGHATPLPVTSTSSASTG
  DTTPLPGTDTSSVSTGHTTPLLVTDASSVSTGDTTRLPVTSPSSASTGHTTPLPVTDTPS
  ASTGDTTPLPVTNASSLSTRHATSLHVTSPSSASTGHATSLPVTDTSAASTGHATPLPVT
  STSSASTGDTTPLPVTDTYSASTGQATPLPVTSLSSVSTGDTTPLPVTSPSSASTGHATP
  LLVTDASSASTGQATPLPVTSLSSVSTGDTTPLPVTSPSSASTGHATSLPVTDTSSASTG
  DTTSLPVTDTSSAYTGDTTSLPVTDTSSSSTGDTTPLLVTETSSVSTGDTTPLPVTDTSS
  ASTGHATPLPVTNTSSVSTGHATPLHVTSPSSASTGHTTPLPVTDASSVSTGHATSLPVT
  DASSVFTGHATSLPVTIPSSASSGHTTPLPVTDASSVSTGHATSLPVTDASSVSTGHATP
  LPVTDASSVSTGHATPLPLTSLSSVSTGDTTPLPVTDTSSASTGQATPLPVTSLSSVSTG
  DTTPLPVTDTSSASTGHATSLPVTDTSSASTGHATPLPDTDTSSASTGHATLLPVTDTSS
  ASIGHATSLPVTDTSSISTGHATPLHVTSPSSASTGHATPLPVTDTSSASTGHANPLHVT
  SPSSASTGHATPLPVTDTSSASTGHATPLPVTSLSSVSTGDTTPLPVTSPSSASTGHTTP
  LPVTDTSSASTGQATALPVTSTSSASTGDTTPLPVTDTSSASTGQATPLPVTSLSSVSTG
  DTTPLPVTSPSSASTGHATPLLVTDASSASTGQATPLPVTSLSSVSTGDTTPLPVTSPSS
  ASTGHATSLPVTDTSSASTGDTTSLPVTDTSSAYTGDTTSLPVTDTSSSSTGDTTPLLVT
  ETSSVSTGHATPLLVTDASSASTGHATPLHVTSPSSASTGDTTPVPVTDTSSVSTGHATP
  LPVTGLSSASTGDTTRLPVTDISSASTGQATPLPVTNTSSVSTGDTMPLPVTSPSSASTG
  HATPLPVTSTSSASTGHATPVPVTSTSSASTGHTTPLPVTDTSSASTGDTTPLPVTSPSS
  ASTGHTTPLHVTIPSSASTGDTSTLPVTGASSASTGHATPLPVTDTSSVSTGHATPLPVT
  SLSSVSTGDTTPLPVTDASSASTGQATPLPVTSLSSVSTGDTTPLLVTDASSVSTGHATP
  LPVTDTSSASTGDTTRLPVTDTSSASTGQATPLPVTSLSSVSTGDTTPLLVTDASSVSTG
  HATPLPVTDTSSASTGDTTRLPVTDTSSASTGQATPLPVTIPSSSSSGHTTPLPVTSTSS
  VSTGHVTPLHVTSPSSASTGHVTPLPVTSTSSASTGHATPLLVTDASSVSTGHATPLPVT
  DASSASTGDTTPLPVTDTSSASTGQATPLPVTSLSSVSTGDTTPLPVTDASSASTGHATP
  LPVTIPSSVSTGDTMPLPVTSPSSASTGHATPLPVTGLSSASTGDTTPLPVTDTSSASTR
  HATPLPVTDTSSASTDDTTRLPVTDVSSASTGHATPLPVTSTSSASTGDTTPLPVTDTSS
  VSTGHATSLPVTSRSSASTGHATPLPVTDTSSVSTGHATPLPVTSTSSVSTGHATPLPVT
  SPSSASTGHATPVPVTSTSSASTGDTTPLPVTNASSLSTGHATPLHVTSPSSASRGDTST
  LPVTDASSASTGHATPLPLTSLSSVSTGDTTPLPVTDTSSASTGQATPLPVTSLSSVSTG
  DTTPLPVTIPSSASSGHTTSLPVTDASSVSTGHGTPLPVTSTSSASTGDTTPLPVTDTSS
  ASTGHATPLPVTDTSSASTGHATPLPVTSLSSVSTGHATPLAVSSATSASTVSSDSPLKM
  ETPGMTTPSLKTDGGRRTATSPPPTTSQTIISTIPSTAMHTRSTAAPIPILPERGVSLFP
  YGAGAGDLEFVRRTVDFTSPLFKPATGFPLGSSLRDSLYFTDNGQIIFPESDYQIFSYPN
  PLPTGFTGRDPVALVAPFWDDADFSTGRGTTFYQEYETFYGEHSLLVQQAESWIRKMTNN
  GGYKARWALKVTWVNAHAYPAQWTLGSNTYQAILSTDGSRSYALFLYQSGGMQWDVAQRS
  GNPVLMGFSSGDGYFENSPLMSQPVWERYRPDRFLNSNSGLQGLQFYRLHREERPNYRLE
  CLQWLKSQPRWPSWGWNQVSCPCSWQQGRRDLRFQPVSIGRWGLGSRQLCSFTSWRGGVC
  CSYGPWGEFREGWHVQRPWQLAQELEPQSWCCRWNDKPYLCALYQQRRPHVGCATYRPPQ
  PAWMFGDPHITTLDGVSYTFNGLGDFLLVGAQDGNSSFLLQGRTAQTGSAQATNFIAFAA
  QYRSSSLGPVTVQWLLEPHDAIRVLLDNQTVTFQPDHEDGGGQETFNATGVLLSRNGSEV
  SASFDGWATVSVIALSNILHASASLPPEYQNRTEGLLGVWNNNPEDDFRMPNGSTIPPGS
  PEEMLFHFGMTWQINGTGLLGKRNDQLPSNFTPVFYSQLQKNSSWAEHLISNCDGDSSCI
  YDTLALRNASIGLHTREVSKNYEQANATLNQYPPSINGGRVIEAYKGQTTLIQYTSNAED
  ANFTLRDSCTDLELFENGTLLWTPKSLEPFTLEILARSAKIGLASALQPRTVVCHCNAES
  QCLYNQTSRVGNSSLEVAGCKCDGGTFGRYCEGSEDACEEPCFPSVHCVPGKGCEACPPN
  LTGDGRHCAALGSSFLCQNQSCPVNYCYNQGHCYISQTLGCQPMCTCPPAFTDSRCFLAG
  NNFSPTVNLELPLRVIQLLLSEEENASMAEVNASVAYRLGTLDMRAFLRNSQVERIDSAA
  PASGSPIQHWMVISEFQYRPRGPVIDFLNNQLLAAVVEAFLYHVPRRSEEPRNDVVFQPI
  SGEDVRDVTALNVSTLKAYFRCDGYKGYDLVYSPQSGFTCVSPCSRGYCDHGGQCQHLPS
  GPRCSCVSFSIYTAWGEHCEHLSMKLDAFFGIFFGALGGLLLLGVGTFVVLRFWGCSGAR
  FSYFLNSAEALP
• Function: Membrane-bound mucin, a family of highly glycosylated proteins that constitute the major component of the mucus, the slimy and viscous secretion covering epithelial surfaces. These glycoproteins play important roles in the protection of the epithelium and are implicated in epithelial renewal and differentiation. Regulates cellular behavior through both anti-adhesive effects on cell-cell and cell-extracellular matrix interactions and its ability to act as an intramembrane ligand for ERBB2. Plays an important role in proliferation and differentiation of epithelial cells by inducing specific phosphorylation of ERBB2. In polarized epithelial cells, segregates ERBB2 and other ERBB receptors and prevents ERBB2 from acting as a coreceptor. The interaction with ERBB2 leads to enhanced expression of CDKN1B. The formation of a MUC4-ERBB2-ERBB3-NRG1 complex leads to down-regulation of CDKN1B, resulting in repression of apoptosis and stimulation of proliferation. Its ability to promote tumor growth may be mainly due to repression of apoptosis as opposed to proliferation.
• Tissue Specificity: Expressed in the thymus, thyroid, lung, trachea, esophagus, stomach, small intestine, colon, testis, prostate, ovary, uterus, placenta, and mammary and salivary glands. Expressed in carcinomas arising from some of these epithelia, such as lung cancers, squamous cell carcinomas of the upper aerodigestive tract, mammary carcinomas, biliary tract, colon, and cervix cancers. Minimally or not expressed in the normal pancreas or chronic pancreatitis, but is highly expressed in pancreatic tumors and pancreatic tumor cell lines.
• Reactome Pathway:
  Defective C1GALT1C1 causes TNPS (R-HSA-5083632)
  Defective GALNT12 causes CRCS1 (R-HSA-5083636)
  Dectin-2 family (R-HSA-5621480)
  O-linked glycosylation of mucins (R-HSA-913709)
  Termination of O-glycan biosynthesis (R-HSA-977068)
  Defective GALNT3 causes HFTC (R-HSA-5083625)

Molecular Interaction Atlas (MIA) of This DOT

43 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Clear cell renal carcinoma	DISBXRFJ	Definitive	Altered Expression	[1]
Matthew-Wood syndrome	DISA7HR7	Definitive	Altered Expression	[2]
Mucositis	DIS3FXDI	Definitive	Biomarker	[3]
Advanced cancer	DISAT1Z9	Strong	Biomarker	[4]
Bone osteosarcoma	DIST1004	Strong	Biomarker	[5]
Carcinoma	DISH9F1N	Strong	Biomarker	[6]
Cervical cancer	DISFSHPF	Strong	Altered Expression	[7]
Cervical carcinoma	DIST4S00	Strong	Altered Expression	[7]
Cholangiocarcinoma	DIS71F6X	Strong	Biomarker	[8]
Colon cancer	DISVC52G	Strong	Altered Expression	[6]
Colon carcinoma	DISJYKUO	Strong	Altered Expression	[6]
Colorectal carcinoma	DIS5PYL0	Strong	Biomarker	[9]
Corneal neovascularization	DISKOGZP	Strong	Biomarker	[10]
Cystic fibrosis	DIS2OK1Q	Strong	Genetic Variation	[11]
Esophageal cancer	DISGB2VN	Strong	Biomarker	[12]
Gastric cancer	DISXGOUK	Strong	Biomarker	[6]
Hepatocellular carcinoma	DIS0J828	Strong	Biomarker	[13]
HER2/NEU overexpressing breast cancer	DISYKID5	Strong	Biomarker	[14]
Inflammatory bowel disease	DISGN23E	Strong	Biomarker	[15]
Lung adenocarcinoma	DISD51WR	Strong	Altered Expression	[16]
Lung cancer	DISCM4YA	Strong	Biomarker	[17]
Lung carcinoma	DISTR26C	Strong	Biomarker	[18]
Nasal polyp	DISLP3XE	Strong	Altered Expression	[19]
Nematode infection	DISVFLRK	Strong	Biomarker	[20]
Osteosarcoma	DISLQ7E2	Strong	Biomarker	[5]
Otitis media	DISGZDUO	Strong	Biomarker	[21]
Ovarian cancer	DISZJHAP	Strong	Altered Expression	[22]
Papillary renal cell carcinoma	DIS25HBV	Strong	Biomarker	[23]
Prostate carcinoma	DISMJPLE	Strong	Biomarker	[24]
Renal cell carcinoma	DISQZ2X8	Strong	Biomarker	[23]
Sickle-cell anaemia	DIS5YNZB	Strong	Genetic Variation	[25]
Squamous cell carcinoma	DISQVIFL	Strong	Biomarker	[18]
Stomach cancer	DISKIJSX	Strong	Biomarker	[6]
Breast cancer	DIS7DPX1	moderate	Biomarker	[26]
Breast carcinoma	DIS2UE88	moderate	Biomarker	[26]
Gastric neoplasm	DISOKN4Y	moderate	Biomarker	[27]
Pancreatic adenocarcinoma	DISKHX7S	moderate	Altered Expression	[28]
Metastatic malignant neoplasm	DIS86UK6	Disputed	Biomarker	[29]
Adenocarcinoma	DIS3IHTY	Limited	Altered Expression	[30]
Fetal growth restriction	DIS5WEJ5	Limited	Biomarker	[31]
Pancreatic ductal carcinoma	DIS26F9Q	Limited	Altered Expression	[32]
Prostate cancer	DISF190Y	Limited	Biomarker	[24]
Prostate neoplasm	DISHDKGQ	Limited	Biomarker	[33]

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the methylation of Mucin-4 (MUC4).	[34]

9 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Tretinoin	DM49DUI	Approved	Tretinoin increases the expression of Mucin-4 (MUC4).	[35]
Decitabine	DMQL8XJ	Approved	Decitabine increases the expression of Mucin-4 (MUC4).	[36]
Selenium	DM25CGV	Approved	Selenium increases the expression of Mucin-4 (MUC4).	[37]
Panobinostat	DM58WKG	Approved	Panobinostat increases the expression of Mucin-4 (MUC4).	[38]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 increases the expression of Mucin-4 (MUC4).	[38]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the mutagenesis of Mucin-4 (MUC4).	[39]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Mucin-4 (MUC4).	[36]
Phencyclidine	DMQBEYX	Investigative	Phencyclidine increases the expression of Mucin-4 (MUC4).	[40]
Forskolin	DM6ITNG	Investigative	Forskolin increases the expression of Mucin-4 (MUC4).	[41]

References

• [1] Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.Medicine (Baltimore). 2016 Apr;95(17):e3225. doi: 10.1097/MD.0000000000003225.
• [2] miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.Oncogene. 2015 Feb 5;34(6):780-8. doi: 10.1038/onc.2014.11. Epub 2014 Mar 10.
• [3] Irinotecan-induced mucositis is associated with changes in intestinal mucins.Cancer Chemother Pharmacol. 2009 Jun;64(1):123-32. doi: 10.1007/s00280-008-0855-y. Epub 2008 Nov 8.
• [4] MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis.Sci Rep. 2019 Nov 13;9(1):16678. doi: 10.1038/s41598-019-53099-0.
• [5] Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.Am J Surg Pathol. 2014 Nov;38(11):1538-44. doi: 10.1097/PAS.0000000000000265.
• [6] Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas.J Transl Med. 2018 Sep 20;16(1):259. doi: 10.1186/s12967-018-1632-2.
• [7] MiR-211 inhibits invasion and epithelial-to-mesenchymal transition (EMT) of cervical cancer cells via targeting MUC4.Biochem Biophys Res Commun. 2017 Apr 1;485(2):556-562. doi: 10.1016/j.bbrc.2016.12.020. Epub 2016 Dec 5.
• [8] Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy.Oncol Rep. 2009 Jan;21(1):49-56.
• [9] Mucin Expression in Colorectal Cancer (CRC): Systematic Review and Meta-Analysis.J Clin Gastroenterol. 2019 Jul;53(6):434-440. doi: 10.1097/MCG.0000000000001050.
• [10] Muc4 expression during blood vessel formation in damaged rat cornea.Curr Eye Res. 2006 Dec;31(12):1011-4. doi: 10.1080/02713680601052155.
• [11] Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis.Nat Commun. 2015 Sep 29;6:8382. doi: 10.1038/ncomms9382.
• [12] The MUC4 membrane-bound mucin regulates esophageal cancer cell proliferation and migration properties: Implication for S100A4 protein.Biochem Biophys Res Commun. 2011 Sep 23;413(2):325-9. doi: 10.1016/j.bbrc.2011.08.095. Epub 2011 Aug 26.
• [13] Synthesis and biological evaluation of novel mono- and bivalent ASGP-R-targeted drug-conjugates.Bioorg Med Chem Lett. 2018 Feb 1;28(3):382-387. doi: 10.1016/j.bmcl.2017.12.032. Epub 2017 Dec 14.
• [14] EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.FASEB J. 2019 Apr;33(4):4851-4865. doi: 10.1096/fj.201701561RRRR. Epub 2019 Jan 8.
• [15] Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.
• [16] Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.Histopathology. 2019 Mar;74(4):545-554. doi: 10.1111/his.13775. Epub 2019 Jan 15.
• [17] Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press.Tumour Biol. 2014 Apr;35(4):3941-2. doi: 10.1007/s13277-013-1390-y. Epub 2013 Nov 17.
• [18] MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.Sci Rep. 2018 Jan 9;8(1):134. doi: 10.1038/s41598-017-18545-x.
• [19] MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2017 Mar;139(3):855-862.e13. doi: 10.1016/j.jaci.2016.06.064. Epub 2016 Sep 14.
• [20] Altered expression of goblet cell- and mucin glycosylation-related genes in the intestinal epithelium during infection with the nematode Nippostrongylus brasiliensis in rat.APMIS. 2006 Apr;114(4):270-8. doi: 10.1111/j.1600-0463.2006.apm_353.x.
• [21] Expression of mucins in mucoid otitis media.J Assoc Res Otolaryngol. 2003 Sep;4(3):384-93. doi: 10.1007/s10162-002-3023-9.
• [22] MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells.Br J Cancer. 2008 Aug 5;99(3):520-6. doi: 10.1038/sj.bjc.6604517.
• [23] Integrated molecular analysis of clear-cell renal cell carcinoma.Nat Genet. 2013 Aug;45(8):860-7. doi: 10.1038/ng.2699. Epub 2013 Jun 24.
• [24] Cell membrane-anchored MUC4 promotes tumorigenicity in epithelial carcinomas.Oncotarget. 2017 Feb 21;8(8):14147-14157. doi: 10.18632/oncotarget.13122.
• [25] Genome-wide association study of erythrocyte density in sickle cell disease patients.Blood Cells Mol Dis. 2017 Jun;65:60-65. doi: 10.1016/j.bcmd.2017.05.005. Epub 2017 May 13.
• [26] Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.Oncogene. 2018 Jan 11;37(2):197-207. doi: 10.1038/onc.2017.327. Epub 2017 Sep 11.
• [27] Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors.Oncogene. 2010 Mar 25;29(12):1753-62. doi: 10.1038/onc.2009.467. Epub 2010 Jan 11.
• [28] The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.Oncogene. 2013 Mar 28;32(13):1714-23. doi: 10.1038/onc.2012.179. Epub 2012 May 14.
• [29] Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the malignant progression of pancreatic cancer by triggering malignancy-related positive feedback loops signaling.J Transl Med. 2014 Nov 4;12:309. doi: 10.1186/s12967-014-0309-8.
• [30] A Tumor-Selective Monoclonal Antibody from Immunization with a Tumor-Associated Mucin Glycopeptide.Sci Rep. 2019 Apr 5;9(1):5662. doi: 10.1038/s41598-019-42076-2.
• [31] Intrauterine growth restriction alters postnatal colonic barrier maturation in rats.Pediatr Res. 2009 Jul;66(1):47-52. doi: 10.1203/PDR.0b013e3181a2047e.
• [32] Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.Scand J Gastroenterol. 2017 May;52(5):595-600. doi: 10.1080/00365521.2017.1290134. Epub 2017 Feb 15.
• [33] Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.Prostate. 2007 Jan 1;67(1):83-106. doi: 10.1002/pros.20505.
• [34] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [35] Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene. 2005 Sep 8;24(40):6143-54. doi: 10.1038/sj.onc.1208756.
• [36] Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. Br J Cancer. 2009 Jan 27;100(2):344-51. doi: 10.1038/sj.bjc.6604845. Epub 2009 Jan 6.
• [37] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [38] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [39] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [40] Microarray Analysis of Gene Expression Alteration in Human Middle Ear Epithelial Cells Induced by Asian Sand Dust. Clin Exp Otorhinolaryngol. 2015 Dec;8(4):345-53. doi: 10.3342/ceo.2015.8.4.345. Epub 2015 Nov 10.
• [41] Diesel Exhaust Particles Enhance MUC4 Expression in NCI-H292 Cells and Nasal Epithelial Cells via the p38/CREB Pathway. Int Arch Allergy Immunol. 2016;171(3-4):209-216. doi: 10.1159/000453033. Epub 2017 Jan 4.